&lt;p&gt;Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease&lt;/p&gt;

White, Darrell E; Zhao, Yang; Jayapalan, Hemalatha; Machiraju, Pattabhi; Periyasamy, Ramu; Ogundele, Abayomi

doi:10.2147/opth.s237832

Cited by 11 publications

(20 citation statements)

References 14 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asian countries have a different view of DED etiology from that of the United States, recognizing tear instability rather than inflammation as the main cause for DED (Watanabe, 2018). Uncertain efficacy, side effects, and high cost also limit the use of these drugs (de Paiva et al, 2019;White et al, 2019;White et al, 2020). In addition to drugs for DED treatment, patients may be using other drugs for co-incident disease.…”

Section: Discussionmentioning

confidence: 99%

Trends in Topical Prescriptional Therapy for Old Patients With Dry Eye Disease in Six Major Areas of China: 2013–2019

Zhu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

The prevalence of dry eye disease (DED) in old patients are high, corresponding to a substantial economic burden. In this cross-sectional study, we analyzed the trends in the topical prescriptional treatment of old patients with DED in six major areas of China. Information on topical drug prescriptions for DED patients aged above 60 years was extracted from the Hospital Prescription Analysis Cooperative Program of China database. Trends in yearly prescriptions and cost were analyzed. The data were further stratified by patient age and sex, drug class, and specific drug. A total of 130,734 prescriptions from 52 hospitals located in six major areas of China were analyzed. The number of prescripptions per year for patients with DED increased from 13,308 in 2013 to 22,074 in 2019, with a corresponding increase in cost of all topical drugs from 1,490,014 Chinese Yuan (CNY) to 2,618,206 CNY. Drugs for the treatment of DED accounted for the largest proportion of the total cost in each year. Ocular lubricants were the main pharmacotherapy agent. Sodium hyaluronate use increased over time, and the drug was used by 65.9% of patients by the end of the study. Pranoprofen was the second most frequently used drug. The most frequently used drugs for co-incident disease were antimicrobials. Treatment patterns for DED haven’t changed, and the most frequently used drug combination was sodium hyaluronate and pranoprofen. In summary, prescription for old patients with DED and the cost of treatment are increasing. Ocular lubricants are the main treatment option, while sodium hyaluronate is the most frequently used drug. The observed trends can lead to more efficient allocation of health care resources in China.

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in Topical Prescriptional Therapy for Old Patients With Dry Eye Disease in Six Major Areas of China: 2013–2019

Zhu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Pain and discomfort is for patients a tough reality and a difficulty for the ophthalmologist. Here, the importance of treating inflammation has been emphasized [108]. The nature of pain as nociceptive or neuropathic [79] is often difficult to identify, as components of both may mix or change over time.…”

Section: Cd44mentioning

confidence: 99%

Impact of Attrition, Intercellular Shear in Dry Eye Disease: When Cells are Challenged and Neurons are Triggered

Setten

2020

IJMS

View full text Add to dashboard Cite

The mechanical component in the pathophysiology of dry eye disease (DED) deserves attention as an important factor. The lubrication deficit induced impaired mechano-transduction of lid pressure to the ocular surfaces may lead to the dysregulation of homeostasis in the epithelium, with sensations of pain and secondary inflammation. Ocular pain is possibly the first sign of attrition and may occur in the absence of visible epithelial damage. Attrition is a process which involves the constant or repeated challenge of ocular surface tissues by mechanical shear forces; it is enhanced by the thinning of corneal epithelium in severe DED. As a highly dynamic process leading to pain and neurogenic inflammation, the identification of the impact of attrition and its potential pathogenic role could add a new perspective to the current more tear film-oriented models of ocular surface disease. Treatment of DED addressing lubrication deficiencies and inflammation should also consider the decrease of attrition in order to stimulate epithelial recovery and neural regeneration. The importance of hyaluronic acid, its molecular characteristics, the extracellular matrix and autoregulative mechanisms in this process is outlined. The identification of the attrition and recognition of its impact in dry eye pathophysiology could contribute to a better understanding of the disease and optimized treatment regimens.

show abstract

“…Eye drops containing hylan A as vehicle have the potential of becoming the platform for the development of the next generation of topical ophthalmic drugs for the treatment of sight threatening diseases such as glaucoma and chronic ocular inflammation [269,270].…”

Section: Hyaluronan Eye Drops As a Vehicle For Active Pharmaceutical mentioning

confidence: 99%

Why Chain Length of Hyaluronan in Eye Drops Matters

Müller-Lierheim¹

2020

Diagnostics

View full text Add to dashboard Cite

The chain length of hyaluronan (HA) determines its physical as well as its physiological properties. Results of clinical research on HA eye drops are not comparable without this parameter. In this article methods for the assessment of the average molecular weight of HA in eye drops and a terminology for molecular weight ranges are proposed. The classification of HA eye drops according to their zero shear viscosity and viscosity at 1000 s−1 shear rate is presented. Based on the gradient of mucin MUC5AC concentration within the mucoaqueous layer of the tear film a hypothesis on the consequences of this gradient on the rheological properties of the tear film is provided. The mucoadhesive properties of HA and their dependence on chain length are explained. The ability of HA to bind to receptors on the ocular epithelial cells, and in particular the potential consequences of the interaction between HA and the receptor HARE, responsible for HA endocytosis by corneal epithelial cells is discussed. The physiological function of HA in the framework of ocular surface homeostasis and wound healing are outlined, and the influence of the chain length of HA on the clinical performance of HA eye drops is illustrated. The use of very high molecular weight HA (hylan A) eye drops as drug vehicle for the next generation of ophthalmic drugs with minimized side effects is proposed and its advantages elucidated. Consequences of the diagnosis and treatment of ocular surface disease are discussed.

show abstract

<p>Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease</p>

Cited by 11 publications

References 14 publications

Trends in Topical Prescriptional Therapy for Old Patients With Dry Eye Disease in Six Major Areas of China: 2013–2019

Trends in Topical Prescriptional Therapy for Old Patients With Dry Eye Disease in Six Major Areas of China: 2013–2019

Impact of Attrition, Intercellular Shear in Dry Eye Disease: When Cells are Challenged and Neurons are Triggered

Why Chain Length of Hyaluronan in Eye Drops Matters

Contact Info

Product

Resources

About